Content uploaded by Matthew G. Davey
All content in this area was uploaded by Matthew G. Davey on Jun 02, 2022
Content may be subject to copyright.
Mesentery and Peritoneum, 2022 9
© Mesentery and Peritoneum. All rights reserved. Mesentery Peritoneum 2022;6:AB009 | http://dx.doi.org/10.21037/map-22-ab009
OncotypeDX© use in patients
diagnosed with early-stage
estrogen receptor positive
James Phelan, Matthew Davey, Ray McLaughlin,
Karl Sweeney, Carmel Malone, Michael Barry,
Maccon Keane, Aoife Lowery, Michael Kerin
Department of Surgery, The Lambe Institute for Translational
Research, National University of Ireland, Galway, Galway, Ireland
Background: Estrogen receptor positive (ER+) breast
cancer is the most common breast cancer molecular
subtype. In recent times, the OncotypeDX© Recurrence
Score (RS) predicts response to chemoendocrine therapies
in early-stage ER+ breast cancers.
Methods: Consecutive female patients diagnosed with
ER+, human epidermal growth factor receptor-2 negative,
lymph node negative (ER+/HER2−/LN−) breast cancer
managed in a single institution between 2005–2015
were included. RS testing was assessed using descriptive
statistics. Survival analyses were performed using log-rank
Kaplan Meier analyses for disease-free survival (DFS) and
overall survival (OS).
Results: A total of 358 patients underwent RS testing, with
a mean RS 18.6±8.1 (range, 3–59). The mean follow up
was 84.1 months. Overall, 85.5% of patients had RS <25
(306/358), of whom 199 received adjuvant chemotherapy
(65.0%). Fourteen and a half percent had RS >25 (52/358)
and 44 received adjuvant chemotherapy (84.6%, 44/52). RS
group (RS <25 versus RS >25) failed to predict DFS or OS
in this cohort (P=0.458). Receiving adjuvant chemotherapy
failed to enhance DFS for those with RS <25 (P=0.588) and
for those with RS >25 (P=0.438). Furthermore, receiving
adjuvant chemotherapy failed to enhance OS for those with
RS <25 (P=0.588) and for those with RS >25 (P=0.438).
All patients received adjuvant endocrine therapy (100%,
Conclusions: RS testing is useful in predicting those who
will benefit from chemoendocrine therapy in early-stage
ER+/HER2−/LN−. Patient substratification is crucial to
personalise treatment specic to each patient.
Keywords: Breast; cancer; estrogen; oncotype; score
Conicts of Interest: The authors have no conicts of interest
Ethical Statement: The authors are accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
Open Access Statement: This is an Open Access article
distributed in accordance with the Creative Commons
Attribution-NonCommercial-NoDerivs 4.0 International
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with
the strict proviso that no changes or edits are made and the
original work is properly cited (including links to both the
formal publication through the relevant DOI and the license).
Cite this abstract as: Phelan J, Davey M, McLaughlin R,
Sweeney K, Malone C, Barry M, Keane M, Lowery A, Kerin
M. AB009. SOH22ABS142. OncotypeDX© use in patients
diagnosed with early-stage estrogen receptor positive breast
cancer. Mesentery Peritoneum 2022;6:AB009.